1. Component-level protection
Most valuable claims start at the basics:
- Antibody sequences and formats (e.g., CDRs, variable regions, humanized/human frameworks)
- Linkers and linker chemistry
- Payloads (cytotoxins) and derivatives
- Specific combinations of antibody + linker + payload
These cover not just the product, but potential future variants and broader compositions. Strategic portfolios often include component patents in addition to full ADC patents.
Trend insights:
- Broader Markush or genus chemical claims on payloads + linkers are used to capture many variants with a single filing.
- Drafting is increasingly tiered: first payload chemistry, then linkers, then full ADC compounds to maximize commercial exclusivity.
2. Fractionated and site-specific claims
Manufacturing and conjugation methods are becoming a fertile claim area because they’re patentable and hard to design around:
- Site-specific conjugation methods (e.g., engineered residues or enzymatic ligation)
- Controlled drug-to-antibody ratio (DAR) techniques
- Purification, homogeneity, and formulation methods
- Methods that improve consistency, efficacy, or safety of ADCs
This adds claims that are independent of specific antibody or payload but are still essential to commercial products.
3. Method of treatment & dosing claims
Beyond composition, many portfolios now layer in method claims including:
- Use of an ADC to treat specific indications
- Dosing / regimen claims
- Patient subpopulation or biomarker-guided treatment claims
- Combination therapy claims (e.g., with checkpoint inhibitors)
These can extend commercial exclusivity even after composition patents expire.
4. Unpredictability & non-obviousness arguments
Because many ADC components were known prior art, practitioners increasingly rely on unexpected results or lack of motivation to combine as part of the claim strategy:
- Demonstrating clinically unexpected efficacy or safety
- Showing that it would not have been obvious to combine known antibodies with known payloads because of toxicity, solubility, stability, etc.
This has been successfully used to defend claims in post-grant proceedings.
5. Enablement & written description pressures
Recent legal developments have tightened what is required to support broad claims:
- According to Federal Circuit decisions, a patent must teach how to make/use the entire scope without undue experimentation — which is challenging in ADC space due to unpredictability of linker behavior and payload release.
- Supreme Court decisions like Amgen v. Sanofi continue to influence antibody claim scope, with broader genus claims requiring more detailed descriptions of representative species.
Practical effect:
Broad genus claims to antibodies or ADC compositions are harder to enable, pushing drafters toward:
- More representative examples
- Nested (tiered) claim structures
- Including detailed structural and functional data
6. Evolving antibody claim drafting
Historically, antibody patents claimed broad antibody classes by function/epitope. After recent case law, drafting has shifted toward:
- CDR-level or sequence-level claims
- Consensus sequences or “CDR scanning” pedigrees
- Claims tied to specific structure + binding properties
This supports enablement and reduces risk of invalidation.
Summary
ADC patent strategy is multi-layered and evolving:
- Early portfolios focused on broad composition protection.
- Modern claims increasingly layer components, methods, treatment uses, and manufacturing innovations to build a patent fortress.
- Legal developments on enablement and antibody genus claims shape how broad or technical these claims can be.
BioTech IP Review 
Leave a comment